Full-Time

Territory Manager

Oklahoma City

Posted on 8/14/2024

Surmodics

Surmodics

201-500 employees

Provides components for diagnostics and medical devices

No salary listed

Senior, Expert

Remote in USA

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Communications
Requirements
  • B.S. or B.A. degree in business, engineering, science, or healthcare field
  • 5+ years experience in medical device sales/clinical support
  • Strong written and verbal communication skills
  • Computer skills including CRM software experience
  • Willingness to travel up to 75%
Responsibilities
  • Create and execute business plans to meet sales objectives
  • Launch new products across geography
  • Strengthen relationships with existing accounts and build relationships with new customers
  • Train customers on product use
  • Maintain product tracking and inventory
  • Complete required training and documentation
  • Forecast regional revenues quarterly/annually
  • Act in compliance with laws and company regulations

Surmodics specializes in providing essential components for in vitro diagnostic (IVD) products and advanced coatings for medical devices. Their IVD offerings include a variety of products such as protein stabilizers, diluents, blockers, substrates, and antibodies, which are vital for creating sensitive immunoassays that detect substances in biological samples. Surmodics also develops advanced coatings for medical devices, including lubricious and hemocompatible coatings, and is known for creating the first drug delivery coating for drug-eluting stents. The company differentiates itself through close collaboration with clients, allowing for rapid product development and commercialization. Surmodics aims to support healthcare and biotechnology advancements by helping clients bring their products to market efficiently.

Company Size

201-500

Company Stage

IPO

Headquarters

Eden Prairie, Minnesota

Founded

1979

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for thrombectomy devices benefits Surmodics' Pounce systems.
  • Increased need for drug-eluting stents aligns with Surmodics' expertise in drug delivery coatings.
  • FDA's focus on fast-tracking innovations could expedite Surmodics' product approvals.

What critics are saying

  • FTC lawsuit against GTCR's acquisition may delay or block the merger.
  • Surmodics' delisting from Nasdaq post-acquisition could impact visibility and capital access.
  • Competitive pressures in thrombectomy market may affect Surmodics' market share.

What makes Surmodics unique

  • Surmodics excels in surface modification and drug-delivery coating technologies.
  • The company offers advanced coatings for medical devices, enhancing performance and compatibility.
  • Surmodics collaborates closely with clients to accelerate product development and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

401(k) Company Match

401(k) Retirement Plan

Company Equity

Stock Options

Company News

Swanson Reed
May 6th, 2025
Minnesota Patent of the Month - April 2025

Surmodics MD, LLC has introduced a groundbreaking solution for pulmonary embolism treatment with its newly patented technology.

MyChesCo
Apr 20th, 2025
FTC Expands Lawsuit Against GTCR's $1.75B Surmodics Acquisition

The FTC, joined by Illinois and Minnesota, has expanded its lawsuit against GTCR over its proposed $1.75 billion acquisition of Surmodics. The complaint argues that the merger would create a dominant player in the market for outsourced hydrophilic coatings, crucial for medical devices, by eliminating competition between Surmodics and Biocoat, Inc., in which GTCR holds a majority stake. This could lead to higher prices, reduced innovation, and lower quality in medical tools.

Urall News
Apr 4th, 2025
Surmodics launches Pounce XL thrombectomy system

Surmodics launches Pounce XL thrombectomy system.

MarketBeat
Jan 5th, 2025
Principal Financial Group Inc. Makes New Investment in Surmodics, Inc. (NASDAQ:SRDX)

Principal Financial Group Inc. makes new investment in Surmodics, Inc. (NASDAQ:SRDX).

MarketBeat
Oct 7th, 2024
Algert Global LLC Makes New $577,000 Investment in Surmodics, Inc. (NASDAQ:SRDX)

Algert Global LLC makes new $577,000 investment in Surmodics, Inc. (NASDAQ:SRDX).

INACTIVE